English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

// Bin Yan 1, * , Zhongsheng Lu 1, * , Zhizheng Ge 2 , Side Liu 3 , Xuegang Guo 4 , Dean Tian 5 , Yuxiu Yang 6 , Xiaobo Li 2 , Wei Gong 3 , Zhiguo Liu 4 , Mei Liu 5 , Bingxi Zhou 6 , Kabing Zhao 1 , Jing Yang 1 and Yunsheng Yang 1 1 Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China 2 Department of Gastroenterology and Hepatology, Renji Hospital, Shanghai, China 3 Department of Gastroenterology and Hepatology, Nanfang Hospital, Guangzhou, Guangdong Province, China 4 Department of Gastroenterology and Hepatology, Xijing Hospital, Xian, Shanxi province, China 5 Department of Gastroenterology and Hepatology, Tongji Hospital, Wuhan, Hubei province, China 6 Department of Gastroenterology and Hepatology, Henan Provincial People’s Hospital, Zhengzhou, Henan Province, China * These authors contributed equally to this work Correspondence to: Yunsheng Yang, email: sunny301ddc@126.com Keywords: randomized clinical trial; endoscopic submucosal dissection; ulcer; lansoprazole; rebamipide Received: September 29, 2017 Accepted: November 15, 2017 Published: January 02, 2018 ABSTRACT Objective: To evaluate the healing efficacy of rebamipide and lansoprazole combination therapy with lansoprazole alone for endoscopic submucosal dissection (ESD)–induced ulcers and clarify the ulcer healing-associated factors. Materials and Methods: Three hundred patients were randomized into control and experimental groups after undergoing ESD. The patients received intravenous pantoprazole (30 mg) every 12 hours and oral rebamipide (100 mg, experimental group) or placebo (control group) three times daily on days 1–3. On days 4–56, patients received oral lansoprazole (30 mg daily) and rebamipide (100 mg) or placebo three times daily. Endoscopic evaluations were performed at postoperative 4 and 8 weeks. Results: At week 4, the ulcer reduction rate was significantly higher in the experimental than in the control group (0.94 ± 0.078 vs. 0.97 ± 0.034; P < 0.001). The ulcer healing (20.3% vs 18.2%; P = 0. 669) and ulcer improvement rates (88.7% vs 94.2%; P = 0. 109) in the two groups were not significantly different. At week 8, the ulcer healing and ulcer improvement rates were 90.6% and 100%, respectively, in both groups. Multivariate analysis showed that the combination treatment was an independent factor associated with ulcer area reduction after ESD. The maximum diameter of the initial ulcer (≥ 35.5 mm vs. < 35.5 mm) was an independent factor associated with the ulcer improvement rate after ESD. Conclusions: The rebamipide and lansoprazole combination therapy can help accelerate the reduction rate of post-ESD ulcer compared with the lansoprazole monotherapy at four weeks of therapy.

oncotarget

WITHDRAWN: A multicenter, randomized, controlled trial of rebamipide plus lansoprazole for the treatment of post-endoscopic submucosal dissection ulcers